An update from Bluejay Diagnostics ( ($BJDX) ) is now available. On December 29, 2025, Bluejay Diagnostics announced it had completed ...

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”) announced that it has completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 ...

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) ("Bluejay" or the "Company") announced that it has completed commercial-scale production of both polyclonal and ...

Therapeutic antibodies, especially polyclonal antibodies, are indispensable in contemporary medicine for addressing a broad spectrum of conditions, including infectious diseases, autoimmune disorders, ...

The paper addresses the problem of optimising the mapping of serum antibody responses against a known antigen. The manuscript describes a method using EM polyclonal epitope mapping to help elucidate ...

Antibodies are a major component of adaptive immunity against invading pathogens. In this presentation, we will describe an analytical approach to characterize the antigen-specific antibody repertoire ...

Antibodies are the number one immune cells that fight against infection and diseases. However, beyond their natural usage, biochemistry has devised several ways in which these antibodies can be ...

GIGA-2339 contains more than 1,000 fully human recombinant anti-HBV antibodies and is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic HBV infection ...

Sarafan ChEM-H, Stanford University, Stanford, California 94305, United States Department of Biochemistry, Stanford University School of Medicine, Stanford, California 94305, United States Sarafan ...

Despite limited information regarding its clinical efficacy, polyclonal antibody treatment with SAB-185 was safe for the treatment of COVID-19 and associated with reduced time to symptom resolution ...

Article subjects are automatically applied from the ACS Subject Taxonomy and describe the scientific concepts and themes of the article. Here, we present a novel IgG1-derived dual-Fc BsAb format ...